S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   287.36 (-0.77%)
AAPL   136.99 (-0.26%)
MSFT   251.33 (-0.72%)
FB   192.70 (+0.74%)
GOOGL   2,170.04 (-1.70%)
AMZN   2,146.79 (+0.02%)
TSLA   658.09 (-7.24%)
NVDA   165.36 (-3.43%)
BABA   86.59 (-1.25%)
NIO   16.34 (-1.92%)
AMD   92.69 (-4.12%)
CGC   5.51 (-6.13%)
MU   68.40 (-1.44%)
T   20.34 (+0.64%)
GE   75.16 (-0.77%)
F   12.47 (-2.96%)
DIS   102.12 (-0.99%)
AMC   11.92 (-8.87%)
PFE   52.44 (+3.53%)
PYPL   80.35 (-1.14%)
NFLX   185.33 (+1.01%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   287.36 (-0.77%)
AAPL   136.99 (-0.26%)
MSFT   251.33 (-0.72%)
FB   192.70 (+0.74%)
GOOGL   2,170.04 (-1.70%)
AMZN   2,146.79 (+0.02%)
TSLA   658.09 (-7.24%)
NVDA   165.36 (-3.43%)
BABA   86.59 (-1.25%)
NIO   16.34 (-1.92%)
AMD   92.69 (-4.12%)
CGC   5.51 (-6.13%)
MU   68.40 (-1.44%)
T   20.34 (+0.64%)
GE   75.16 (-0.77%)
F   12.47 (-2.96%)
DIS   102.12 (-0.99%)
AMC   11.92 (-8.87%)
PFE   52.44 (+3.53%)
PYPL   80.35 (-1.14%)
NFLX   185.33 (+1.01%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   287.36 (-0.77%)
AAPL   136.99 (-0.26%)
MSFT   251.33 (-0.72%)
FB   192.70 (+0.74%)
GOOGL   2,170.04 (-1.70%)
AMZN   2,146.79 (+0.02%)
TSLA   658.09 (-7.24%)
NVDA   165.36 (-3.43%)
BABA   86.59 (-1.25%)
NIO   16.34 (-1.92%)
AMD   92.69 (-4.12%)
CGC   5.51 (-6.13%)
MU   68.40 (-1.44%)
T   20.34 (+0.64%)
GE   75.16 (-0.77%)
F   12.47 (-2.96%)
DIS   102.12 (-0.99%)
AMC   11.92 (-8.87%)
PFE   52.44 (+3.53%)
PYPL   80.35 (-1.14%)
NFLX   185.33 (+1.01%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   287.36 (-0.77%)
AAPL   136.99 (-0.26%)
MSFT   251.33 (-0.72%)
FB   192.70 (+0.74%)
GOOGL   2,170.04 (-1.70%)
AMZN   2,146.79 (+0.02%)
TSLA   658.09 (-7.24%)
NVDA   165.36 (-3.43%)
BABA   86.59 (-1.25%)
NIO   16.34 (-1.92%)
AMD   92.69 (-4.12%)
CGC   5.51 (-6.13%)
MU   68.40 (-1.44%)
T   20.34 (+0.64%)
GE   75.16 (-0.77%)
F   12.47 (-2.96%)
DIS   102.12 (-0.99%)
AMC   11.92 (-8.87%)
PFE   52.44 (+3.53%)
PYPL   80.35 (-1.14%)
NFLX   185.33 (+1.01%)
NASDAQ:NBIX

Neurocrine Biosciences (NBIX) Stock Forecast, Price & News

$85.72
+0.35 (+0.41%)
(As of 05/20/2022 03:52 PM ET)
Add
Compare
Today's Range
$84.01
$86.18
50-Day Range
$75.79
$100.07
52-Week Range
$71.88
$108.01
Volume
8,686 shs
Average Volume
877,646 shs
Market Capitalization
$8.19 billion
P/E Ratio
119.06
Dividend Yield
N/A
Beta
0.7
30 days | 90 days | 365 days | Advanced Chart
Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Neurocrine Biosciences logo

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
900
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$1.25 per share
Book Value
$14.56 per share

Profitability

Net Income
$89.60 million
Pretax Margin
7.92%

Debt

Price-To-Earnings

Miscellaneous

Free Float
91,372,000
Market Cap
$8.19 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/20/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.72 out of 5 stars

Medical Sector

52nd out of 1,420 stocks

Biological Products, Except Diagnostic Industry

5th out of 209 stocks

Analyst Opinion: 4.2Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -













Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

Is Neurocrine Biosciences a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Neurocrine Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NBIX, but not buy additional shares or sell existing shares.
View analyst ratings for Neurocrine Biosciences
or view top-rated stocks.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Neurocrine Biosciences
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Wednesday, May, 4th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.35 by $0.21. The business had revenue of $310.60 million for the quarter, compared to analysts' expectations of $304.07 million. Neurocrine Biosciences had a net margin of 5.91% and a trailing twelve-month return on equity of 5.30%. Neurocrine Biosciences's revenue for the quarter was up 31.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.33 EPS.
View Neurocrine Biosciences' earnings history
.

What price target have analysts set for NBIX?

17 brokerages have issued 1 year target prices for Neurocrine Biosciences' shares. Their forecasts range from $76.00 to $154.00. On average, they expect Neurocrine Biosciences' share price to reach $112.21 in the next twelve months. This suggests a possible upside of 30.7% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Neurocrine Biosciences' key executives?
Neurocrine Biosciences' management team includes the following people:
What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences CEO Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among Neurocrine Biosciences' employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Square (SQ) and Salesforce (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.18%), Bellevue Group AG (3.16%), Bank of New York Mellon Corp (1.78%), Deerfield Management Company L.P. Series C (1.73%), Eaton Vance Management (1.52%) and DSM Capital Partners LLC (1.41%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends for Neurocrine Biosciences
.

Which major investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Eaton Vance Management, Zurcher Kantonalbank Zurich Cantonalbank , BNP Paribas Arbitrage SA, Citigroup Inc., Bank of New York Mellon Corp, Bellevue Group AG, Renaissance Technologies LLC, and Verition Fund Management LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin, and William H Rastetter.
View insider buying and selling activity for Neurocrine Biosciences
or view top insider-selling stocks.

Which major investors are buying Neurocrine Biosciences stock?

NBIX stock was bought by a variety of institutional investors in the last quarter, including Polar Capital Holdings Plc, American Century Companies Inc., Wellington Management Group LLP, Deerfield Management Company L.P. Series C, GW&K Investment Management LLC, Congress Asset Management Co. MA, Connor Clark & Lunn Investment Management Ltd., and Rice Hall James & Associates LLC.
View insider buying and selling activity for Neurocrine Biosciences
or or view top insider-buying stocks.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $85.84.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences has a market capitalization of $8.20 billion and generates $1.13 billion in revenue each year. The company earns $89.60 million in net income (profit) each year or $0.72 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

Neurocrine Biosciences employs 900 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is www.neurocrine.com.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 617-7600, via email at [email protected], or via fax at 858-617-7602.

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.